MorphoSys Signs Manufacturing Agreement with Boehringer Ingelheim
(Thomson Reuters ONE) -
MorphoSys AG /
MorphoSys Signs Manufacturing Agreement with Boehringer Ingelheim
Processed and transmitted by Thomson Reuters.
The issuer is solely responsible for the content of this announcement.
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) and Boehringer Ingelheim
announced today the signing of a biopharmaceutical manufacturing agreement for
therapeutic antibodies. The agreement covers the process development and
manufacturing of additional clinical material for MorphoSys's proprietary MOR208
program and other drug candidates. MOR208, a potent monoclonal anti-CD19
antibody, is in development for the treatment of chronic lymphocytic leukemia
and potentially other B-cell malignancies. The program is currently being
evaluated in a phase 1 clinical trial in the USA by MorphoSys's partner Xencor
Inc.
"Adding an additional supplier to our proprietary development set-up will help
to prevent any bottlenecks in clinical trial supply in the years ahead",
commented Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG.
"Additionally, establishing a commercial manufacturing process with Boehringer
Ingelheim early in the development of MOR208 will clearly increase the value of
this program."
Simon Sturge, Corporate Senior Vice President of the Biopharmaceuticals Division
at Boehringer Ingelheim, said: "We believe that the combination of MorphoSys's
successful track record in the discovery and clinical development of antibody-
based therapeutics and our proven competence in technical development and
manufacturing will be an optimal fit. We look forward to supporting the team at
MorphoSys with robust manufacturing processes for clinic and market supply."
"Boehringer Ingelheim is a world-class contract manufacturing organization and
we are delighted to sign this agreement with them today", commented Dr. Arndt
Schottelius, Chief Development Officer of MorphoSys AG. "Our proprietary
pipeline currently comprises eight fully-owned therapeutic antibodies in
addition to two co-development candidates selected within the Novartis alliance.
With MOR103, a HuCAL-based anti-inflammatory antibody targeting GM-CSF, and
MOR202, a HuCAL-based cancer antibody targeting CD38, as well as MOR208, we will
investigate three proprietary drug programs in clinical trials in 2011."
About MorphoSys:
MorphoSys is an independent biotechnology company that develops novel antibodies
for therapeutic, diagnostic and research applications. The Company's HuCAL
technology is one of the most powerful methods available for generating fully
human antibodies. By successfully applying this and other proprietary
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human health-care.
Through its alliances with some of the world's leading pharmaceutical companies,
MorphoSys has created a pipeline of more than 60 drug candidates. The Company is
expanding its drug pipeline by adding new partnered programs, and by building a
portfolio of fully-owned therapeutic antibodies. For its proprietary portfolio,
the Company is focused on the areas of oncology and inflammation. Its most
advanced program MOR103, a first-in-class, fully human antibody against GM-CSF,
is currently being tested in a Phase Ib/IIa trial in rheumatoid arthritis
patients. Via its business unit AbD Serotec, MorphoSys is expanding the reach of
its technologies in the diagnostics and research markets. MorphoSys is
headquartered in Munich, Germany and listed on the Frankfurt Stock Exchange
under the symbol "MOR". For further information, visithttp://www.morphosys.com/
HuCAL(®), HuCAL GOLD(®), HuCAL PLATINUM(®), CysDisplay(®) and RapMAT(®) are
registered trademarks of MorphoSys; arYla(TM) is a trademark of MorphoSys.
About Boehringer Ingelheim:
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical
companies. Headquartered in Ingelheim, Germany, it operates globally with 142
affiliates in 50 countries and more than 41,500 employees. Since it was founded
in 1885, the family-owned company has been committed for 125 years to
researching, developing, manufacturing and marketing novel products of high
therapeutic value for human and veterinary medicine.
Today, Boehringer Ingelheim is one of the world's leading companies for contract
development and manufacture of biopharmaceuticals. All types of services from
mammalian cell line or microbial strain development to final drug production can
be delivered within a one-stop-shop concept. Boehringer Ingelheim delivers
services for pre-clinical development up to global market supply with a strong
commitment to its customers at its manufacturing facilities for mammalian cell
culture and microbial fermentation. Boehringer Ingelheim has brought 18
molecules to market and has many years of experience in multiple molecule
classes such as monoclonal antibodies, recombinant proteins, interferons,
enzymes, fusion molecules and plasmid DNA. Furthermore, high-titer platform
technologies for new antibody mimetic formats such as scaffold proteins and
antibody fragments are available for the manufacture of customer products.
Contact us:bio-cmo(at)boehringer-ingelheim.com
www.biopharma-cmo.com
This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.
For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122
Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454
Jessica Kulpi
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332
investors(at)morphosys.com
Boehringer Ingelheim
Corporate Communications
Media + PR
Heidrun Thoma
55216 Ingelheim/Germany
+49 6132 77 3966
E-Mail:press(at)boehringer-ingelheim.com
Twitter:www.twitter.com/boehringer
--- End of Message ---
MorphoSys AG
Lena-Christ-Str. 48 Martinsried / München Germany
WKN: 663200;ISIN: DE0006632003;Index:TecDAX,CDAX,Prime All Share,TECH All Share,HDAX,MIDCAP;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
Press Release:
http://hugin.info/130295/R/1497028/432769.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE
[HUG#1497028]
Unternehmensinformation / Kurzprofil:
Datum: 16.03.2011 - 07:31 Uhr
Sprache: Deutsch
News-ID 52469
Anzahl Zeichen: 8499
contact information:
Town:
Martinsried / München
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 272 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MorphoSys Signs Manufacturing Agreement with Boehringer Ingelheim"
steht unter der journalistisch-redaktionellen Verantwortung von
MorphoSys AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
